journal article·2018-05-16

Dual Suppression Effect of Magnetic Induction Heating and Microencapsulation on Ice Crystallization Enables Low-Cryoprotectant Vitrification of Stem Cell–Alginate Hydrogel Constructs

Xiaoli Liu, Gang Zhao, Zhongrong Chen, Fazil Panhwar, Xiaoming He

ACS Applied Materials & Interfaces· Volume 10· Issue 19
Publisher page

Abstract

Stem cells microencapsulated in hydrogel as stem cell–hydrogel constructs have wide applications in the burgeoning cell-based medicine. Due to their short shelf life at ambient temperature, long-term storage or banking of the constructs is essential to the “off-the-shelf” ready availability needed for their widespread applications. As a high-efficiency, easy-to-operate, low-toxicity, and low-cost method for long-term storage of the constructs, low-cryoprotectant (CPA) vitrification has attracted tremendous attention recently. However, we found many cells in the stem cell–alginate constructs (∼500 μm in diameter) could not attach to the substrate post low-CPA vitrification with ∼2 M penetrating CPAs. To address this problem, we introduced nanowarming via magnetic induction heating (MIH) of Fe3O4 nanoparticles to minimize recrystallization and devitrification during the warming step of the low-CPA vitrification procedure. Our results indicate that high-quality stem cell–alginate hydrogel constructs with an intact microstructure, high immediate cell survival (>80%), and greatly improved attachment efficiency (by nearly three times, 68% versus 24%) of the encapsulated cells could be obtained post-cryopreservation with nanowarming. Moreover, the cells encapsulated in the cell–hydrogel constructs post-cryopreservation maintained normal proliferation under 3D culture and retained intact biological function of multilineage differentiation. This novel low-CPA vitrification approach for cell cryopreservation enabled by the combined use of alginate hydrogel microencapsulation and Fe3O4 nanoparticles-mediated nanowarming may be valuable in facilitating the widespread application of stem cells in the clinic.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Reproductive Biology and Fertility · Tissue Engineering and Regenerative Medicine · 3D Printing in Biomedical Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Electronic Science and Technology, University of Science and Technology of China, Hefei 230027, Anhui, China

Fischell Department of Bioengineering, University of Maryland, College Park, Maryland 20742, United States

Funding

National Institute of Biomedical Imaging and Bioengineering · National Natural Science Foundation of China

References (63)

Show source-provided references
1. 10.1016/j.stem.2009.06.01610.1016/j.stem.2009.06.016 ↗
2. 10.1089/ten.tea.2013.019810.1089/ten.tea.2013.0198 ↗
3. 10.1016/j.stemcr.2015.04.00810.1016/j.stemcr.2015.04.008 ↗
4. 10.1002/bit.2225010.1002/bit.22250 ↗
5. 10.1038/ncomms1330610.1038/ncomms13306 ↗
6. 10.1021/acsbiomaterials.7b0022910.1021/acsbiomaterials.7b00229 ↗
7. 10.1016/j.stemcr.2017.04.02710.1016/j.stemcr.2017.04.027 ↗
8. 10.1021/acsami.7b1753310.1021/acsami.7b17533 ↗
9. 10.1021/acsami.7b1853510.1021/acsami.7b18535 ↗
10. 10.1021/acsami.7b1096010.1021/acsami.7b10960 ↗
11. 10.1021/acsami.7b0072810.1021/acsami.7b00728 ↗
12. 10.1016/j.stemcr.2015.04.00810.1016/j.stemcr.2015.04.008 ↗
13. 10.1016/j.stem.2015.12.00410.1016/j.stem.2015.12.004 ↗
14. 10.1016/S0142-9612(98)00107-010.1016/S0142-9612(98)00107-0 ↗
15. 10.1016/j.biomaterials.2009.09.07110.1016/j.biomaterials.2009.09.071 ↗
16. 10.1016/j.biomaterials.2009.12.00410.1016/j.biomaterials.2009.12.004 ↗
17. 10.1007/s00125-013-2906-010.1007/s00125-013-2906-0 ↗
18. 10.1038/nm0103-10410.1038/nm0103-104 ↗
19. 10.1021/acsami.5b1125810.1021/acsami.5b11258 ↗
20. 10.1021/acsami.6b0829210.1021/acsami.6b08292 ↗
21. 10.1016/j.biomaterials.2013.12.07310.1016/j.biomaterials.2013.12.073 ↗
22. 10.1016/j.jconrel.2008.08.01010.1016/j.jconrel.2008.08.010 ↗
23. 10.1016/j.biomaterials.2009.03.00510.1016/j.biomaterials.2009.03.005 ↗
24. 10.1016/j.ijpharm.2015.02.04710.1016/j.ijpharm.2015.02.047 ↗
25. 10.1080/0265204041000172925010.1080/02652040410001729250 ↗
26. 10.1093/humrep/17.5.127410.1093/humrep/17.5.1274 ↗
27. 10.1016/j.biomaterials.2007.11.02710.1016/j.biomaterials.2007.11.027 ↗
28. 10.1038/313573a010.1038/313573a0 ↗
29. 10.1021/acsami.7b1218910.1021/acsami.7b12189 ↗
30. 10.1016/0142-9612(96)85562-110.1016/0142-9612(96)85562-1 ↗
31. 10.1016/j.cryobiol.2008.03.00510.1016/j.cryobiol.2008.03.005 ↗
32. 10.1016/j.cryobiol.2015.08.01210.1016/j.cryobiol.2015.08.012 ↗
33. 10.1007/s10544-009-9363-z10.1007/s10544-009-9363-z ↗
34. 10.1016/j.biomaterials.2009.03.00510.1016/j.biomaterials.2009.03.005 ↗
35. 10.1016/j.actbio.2016.01.02610.1016/j.actbio.2016.01.026 ↗
36. 10.1126/scitranslmed.aah458610.1126/scitranslmed.aah4586 ↗
37. 10.1016/j.tiv.2005.06.03410.1016/j.tiv.2005.06.034 ↗
38. 10.2147/IJN.S1324410.2147/IJN.S13244 ↗
39. 10.1021/nn200749610.1021/nn2007496 ↗
40. 10.2147/IJN.S1045810.2147/IJN.S10458 ↗
41. 10.1021/acsami.5b0387310.1021/acsami.5b03873 ↗
42. 10.1039/c3ra47043a10.1039/c3ra47043a ↗
43. 10.1371/journal.pone.008508910.1371/journal.pone.0085089 ↗
44. Jay J. M. · 1992 · 16610.1007/978-94-011-6480-1_7 ↗
45. 10.1016/j.toxlet.2009.03.01410.1016/j.toxlet.2009.03.014 ↗
46. 10.2217/nnm.15.1410.2217/nnm.15.14 ↗
47. 10.1038/sj.onc.120752110.1038/sj.onc.1207521 ↗
48. 10.2147/IJN.S1045810.2147/IJN.S10458 ↗
49. 10.1088/0953-8984/18/15/L0410.1088/0953-8984/18/15/L04 ↗
50. 10.1002/adhm.20120034110.1002/adhm.201200341 ↗
51. 10.1002/adhm.20150013310.1002/adhm.201500133 ↗
52. 10.1002/adfm.20150304710.1002/adfm.201503047 ↗
53. 10.1142/S233954781450020410.1142/S2339547814500204 ↗
54. 10.1007/BF0023213010.1007/BF00232130 ↗
55. 10.1093/humrep/den39710.1093/humrep/den397 ↗
56. Center for Biologics Evaluation and Research, U.S. Food and Drug Administration. Guidance for FDA reviewers and sponsors: Content and review of chemistry, manufacturing, and control (CMC) information for human somatic cell therapy investigational new drug applications (INDs). U.S. Food and Drug Administration, Washington, DC, USA, 2008.
57. 10.3727/00000000278398540410.3727/000000002783985404 ↗
58. 10.3727/00000000778346500010.3727/000000007783465000 ↗
59. 10.3727/096368909X48176410.3727/096368909X481764 ↗
60. 10.3727/096368912X65512710.3727/096368912X655127 ↗
61. 10.1093/humrep/14.4.101310.1093/humrep/14.4.1013 ↗
62. 10.1016/j.ijheatmasstransfer.2017.06.03610.1016/j.ijheatmasstransfer.2017.06.036 ↗
63. 10.1021/acsbiomaterials.7b0020110.1021/acsbiomaterials.7b00201 ↗